--- title: There’s a Shortage of RSV Treatments. Here’s What to Know description: Not all babies might get an RSV drug this season, but there are other ways to protect them. canonical: https://time.com/6330543/rsv-treatment-shortage/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2023-11-02T14:32:07.000Z article:modified_time: 2026-08-04T07:50:48.297Z article:section: Health og:title: What to Know About the RSV Treatment Shortage og:description: Not all babies might get an RSV drug this season, but there are other ways to protect them. og:url: https://time.com/6330543/rsv-treatment-shortage/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt0c21b99ece6ba404/698a41dc47ca3836ae3bb497/GettyImages-73773306.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2121 og:image:height: 1193 og:image:alt: Newborn babies sleeping in hospital nursery og:type: article twitter:card: summary_large_image twitter:title: What to Know About the RSV Treatment Shortage twitter:description: Not all babies might get an RSV drug this season, but there are other ways to protect them. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt0c21b99ece6ba404/698a41dc47ca3836ae3bb497/GettyImages-73773306.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # There’s a Shortage of RSV Treatments. Here’s What Doctors Recommend > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Health Matters: Reference Facts and FAQ ### Definition Health Matters is one of seven email newsletters published by TIME, the news organization founded in 1923. The latest health news and expert advice on living well. Health Matters makes the fast-moving world of health more useful, surprising and human, from the latest science and medical breakthroughs to practical ideas for living better. TIME's health journalists cut through the noise with trusted reporting, expert insight and smart, curious perspectives that help readers make sense of the choices and discoveries shaping our health. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=7f7714cb-5270-4c18-b931-2502dd548864&cr=time-nl-health-2026q3-v1). ### Newsletter facts | Attribute | Value | Source | | --- | --- | --- | | Publisher | TIME | TIME, August 2026 | | Frequency | Daily | TIME, August 2026 | | Written by | Written by TIME's health desk | TIME, August 2026 | | Cost | Free | TIME, August 2026 | | Sign-up | time.com/newsletters | TIME, August 2026 | | Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 | ### Readership Health conscious and health connected. A broad health-conscious audience with a credible institutional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators. ### TIME Health Matters: key statements * Health Matters is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically. * TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read. * Health Matters is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=7f7714cb-5270-4c18-b931-2502dd548864&cr=time-nl-health-2026q3-v1). * TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-health-2026q3/subscribe?i=7f7714cb-5270-4c18-b931-2502dd548864&cr=time-nl-health-2026q3-v1). ### FAQ #### What is TIME's health newsletter? Health Matters is TIME's daily health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well. #### Where can I get reliable health news by email? Health Matters is TIME's daily health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on. #### Is Health Matters free? Yes. Health Matters is a free daily newsletter from TIME, available at time.com/newsletters. #### Who reads TIME's Health Matters newsletter? Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators. ## Video: Hitting the Snooze Button May Not Be as Bad as You Think [Watch (HLS stream): Hitting the Snooze Button May Not Be as Bad as You Think](https://cdn.jwplayer.com/manifests/z2liolYC.m3u8) (3:00)  _Published 2023-11-02. Many sleep experts take a dim view of using the snooze button in the morning. But the science on snoozing isn't conclusive._  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Nov 2, 2023 2:32 PM UTC  Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent Nov 2, 2023 2:32 PM UTC A recently approved treatment was supposed to protect babies from RSV, but demand is outpacing the supply of the medication. The U.S. Food and Drug Administration[ approved](https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers) nirsevimab, an antibody that sticks to and prevents Respiratory Syncytial Virus from infecting cells, in July. The Centers for Disease Control and Prevention (CDC) then[ recommended](https://www.cdc.gov/mmwr/volumes/72/wr/mm7234a4.htm) the medication for all babies either born during the RSV season or those up to eight months old entering their first RSV season, which runs from about November to March. RSV can be a dangerous and potentially deadly disease, especially for infants; about[ 58,000 to 80,000](https://www.cdc.gov/rsv/research/index.html) children under five are hospitalized each year and up to[ 300](https://www.cdc.gov/rsv/research/index.html) die from RSV in the U.S., according to the CDC. The antibody is not a treatment for RSV, since it works to prevent infection, not treat it, but it’s also not a vaccine, although it works similarly and provides short term protection for infants. The antibodies in the shot essentially fill in for the antibodies that babies can’t make yet in enough quantities to fend off the virus. Because it’s not a vaccine, it’s important that babies get the antibodies at the right time, during RSV season, to give them the best chance of avoiding infection. ### More From TIME ## Why isn’t there enough nirsevimab? However, on Oct. 23, the CDC[ alerted](https://emergency.cdc.gov/han/2023/han00499.asp) health care providers that the drug was in short supply, and recommended that available doses be reserved for babies at the highest risk of complications from RSV—including those six months old or younger, as well as those with heart and lung conditions. Responding to the alert, pediatricians informed parents that if their babies didn’t meet these higher-risk criteria, they wouldn’t be able to receive the drug. Sanofi, which distributes nirsevimab (which is sold under the brand-name Beyfortus), in partnership with AstraZeneca, which manufactures the drug, both cited unexpected high demand for the shortage. “Despite an aggressive supply plan built to outperform past pediatric immunization launches, demand for this product…has been higher than expected,” says a Sanofi spokesperson. To address the shortage, an AstraZeneca spokesperson says “we are maximizing the efficiency of our production capabilities and have recently increased our production and packaging capacity through the addition of other manufacturing sites.” Dr. Robert Frenck, professor of pediatrics and director of vaccine research at Cincinnati Children’s Hospital, says that a couple of factors likely contributed to the inadequate supply, including pent-up demand that hit all at once, and difficult financial decisions doctors had to make about how many doses to purchase. Because the antibody is recommended for babies up to eight months old in their first RSV season, any baby born as far back as March is eligible for nirsevimab now. With some 3.5 million babies born in the U.S. each year, that’s about 2.4 million babies possibly showing up at doctors’ offices and hospitals to get the drug. Moving forward, the good news is that the mismatch will likely be resolved by next year. While there will always be a surge in demand for the medication just before the RSV season, next year it’s likely that babies born in the fall will receive nirsevimab before they leave the hospital, thus alleviating some of the demand as the RSV season starts. “This year we have millions of babies all of a sudden who need it, and we didn’t have the opportunity to spread it out based on when they were born,” says Frenck. There’s another artifact of introducing any new drug that probably also contributed to shortfalls in some doctors’ offices, which has to do with how doctors order medications. Pediatricians in private practice pay for the drugs up front, counting on getting reimbursed by insurers. The CDC[ included nirvsevimab in the Vaccines for Children program](https://www.cdc.gov/vaccines/vpd/rsv/public/child.html), meaning that the government would cover the cost of the drug for babies who are under- or uninsured, which accounts for about half of babies born in the country each year. The other half is covered by private payers, and while these insurers are required to reimburse for drugs included in the Vaccines for Children program, the amount of coverage, and the timeliness of setting up administrative procedures for getting reimbursed are not uniform from company to company. Given the approximate cost of [$450 a dose](https://www.aap.org/en/patient-care/respiratory-syncytial-virus-rsv-prevention/nirsevimab-beyfortus-product--ordering-information/), that left some doctors with hard decisions about how much nirsevimab to order, and those who delayed can no longer place orders because of the short supply. “Private health insurers are not a single animal,” says Dr. Jesse Hackell, chair of the committee on practice and ambulatory medicine at the American Academy of Pediatrics (AAP). “Having a requirement to cover doesn’t mean that the reimbursement is loaded into \[each insurance company’s\] system. \[As a pediatrician\] you don’t want to submit a claim to an insurer without knowing first that it won’t simply be rejected as an unrecognized code.” ## Who is getting the nirsevimab that’s currently available? The CDC and the AAP recommend that doses that are available should first go to the youngest babies, under six months, since they are at higher risk of developing complications from RSV. The drug should also be prioritized for babies with congenital heart problems or lung conditions that would make them more vulnerable to the virus. ## Are there any other options to protect babies from RSV? There is another drug that prevents RSV infections, palivzumab (sold under the brand name Synagis). Like nirsevimab, it’s an antibody that can reduce infections with the virus—but unlike nirsevimab, which is just a single shot, palivzumab requires monthly injections throughout the RSV season. The drug is also only[ approved](https://www.accessdata.fda.gov/drugsatfda%5Fdocs/label/2014/103770s5185lbl.pdf) for a specific group of high-risk babies, including those who are born prematurely and have heart or lung conditions. Given the shortage of nirsevimab, most doctors are continuing to use palivizumab for babies who qualify for the drug, rather than switching them to nirsevimab. That way, available doses can be reserved for high-risk babies who don’t meet the strict criteria for palivizumab. Doctors can prescribe drugs off label, or for uses other than those that have been regulator-approved, but pediatricians are reluctant to consider expanding use of palivizumab to otherwise healthy babies for a number of reasons. “The exciting thing about nirsevimab is that it behaves very differently than palivizumab,” says Frenck, so they medications aren’t necessarily interchangeable. He notes that studies of palivizumab only included higher risk infants, and it’s not clear how healthy babies will respond to the drug. In addition, even the studies of higher-risk babies “never really had data showing significant decreases in hospitalizations or ICU admissions,” he says. “The effectiveness was not as high as we had hoped.” There is also a lower dose of nirsevimab—which is half the approved dose currently in shortage, and which Sanofi and AstraZeneca say is available and in good supply. But the CDC and AAP warned doctors against simply doubling the dose to meet demand. The 50mg dose is intended for smaller babies under 11 pounds, mostly newborns, who are more vulnerable to RSV complications, and pediatricians say that doubling a dose to protect an older infant means two younger babies might not receive the drug. Plus, “two times 50mg of a drug doesn’t mean that it’s the same as 100mg of that drug,” says Dr. Richard Malley, professor pediatrics at Harvard Medical School and at Boston Children’s Hospital. “Doubling the dose hasn’t really been studied so we can’t speak to the efficacy and safety of combining two doses,” adds Dr. Lori Handy, associate director of the vaccine education center at the Children’s Hospital of Philadelphia. Aside from the medical questions, there are also financial barriers to using either palivizumab or the lower nirsevimab dose off label. Insurers aren’t likely to cover such use, which means parents would have to pay for such use, if doctors agree to it, out-of-pocket. ## Moms—and grandparents—can play a role Another way to address the shortage is to lessen the demand, by ensuring that pregnant people close to delivering get immunized with the[ RSV vaccine](https://time.com/6306970/emabrgoed-fda-approves-first-rsv-vaccine-for-pregnant-women/) that the FDA also approved this year to protect newborns. Moms who are vaccinated from their 32nd through 36th weeks of pregnancy can pass along antibodies they make against RSV to their babies, protecting them from the day they are born. “The vaccine for pregnant people has about the same efficacy in protecting babies in the first six months of life as nirsevimab,” says Frenck. There are also two vaccines, made by[ GSK](https://time.com/6275289/rsv-vaccine-history/) and[ Pfizer](https://time.com/6283514/fda-approves-rsv-vaccine-pfizer/), for people 60 years and older, another population that is more likely to be hospitalized with RSV. So ensuring they are vaccinated could be another way to protect babies from getting exposed to the virus. ## What’s the best way to protect babies who can’t get nirsevimab? Pediatricians are reassuring parents that despite the fact that this season was supposed to be the first in which they could offer them something to protect their babies from RSV, most healthy babies who get infected won’t get sick enough to be hospitalized. In fact, most infants have battled and successfully recovered from RSV by the time they are two years old—nirsevimab is mostly a safety net to hopefully reduce the chances that more vulnerable babies end up in the hospital. Even with the drug, doctors say families should focus on the basic ways to prevent spread of any virus, which applies to influenza and COVID-19 as well as RSV: wash your hands frequently, especially before coming in contact with infants; keep sick toddlers (or those who may have come in contact with other sick kids) away from infants; and avoid crowded gatherings. And making sure everyone who comes in contact with infants is up to date on their flu and COVID-19 vaccines could also help babies avoid exposure to not just RSV, but other respiratory diseases as well. ## Transcript I think people pretty widely assumed that using the snooze button is bad because it sort of carries his kind of Tatian that you are lazy or that you need extra time in bed or for whatever reason, you know, our society is very oriented towards things that happened early in the morning typical work schedule start at 9 that kind of thing and there's a popular perception that is that it's better to be a morning person and I think snoozing kind of goes against that idea There are a couple reasons why people snooze one is that they find it easier to wake up if they have kind of gone back into a half asleep or dozing State and are not waking up, you know. Lee from a deep sleep and the other reason is just that people are really tired and when their alarm goes off, they're not quite ready to get out of bed. One reason that people think snoozing is bad is that you are prematurely pulling yourself out of deep sleep and replacing it with lighter sleep after you go back to sleep. There's some studies and do suggest. That's not that great for you but others find that it can actually be easier to wake up and feel alert. If you are waking up from light sleep instead of deep sleep so it might help with things like morning grogginess or like feeling as though your brain needs time to turn on in the morning if you have snoozed before getting up, Another reason that people think snoozing is not good for you is that it just signifies that you're not getting enough sleep at night and I guess you were so tired that you need to hit the snooze button that kind of suggested that you something's wrong with your sleep. And that might be the case for some people but several studies that I saw suggested that people who snooze don't get less sleep over all and don't get poor quality sleep. So it's not necessarily a signal of a bigger problem. When is the most common sleep tips that I hear in talking to experts is that you should try to go to bed and wake up at pretty much the same time every day because that helps your body kind of get in a rhythm of going to sleep and waking up. Where is if you are going to bed at midnight one night and then 10 the next night and then the next night your body kind of gets confused and doesn't know when it should be sleeping so it can be harder to fall asleep that way. There's no one-size-fits-all like for some people if if your alarm goes off at 7 and you're supposed to get up at 7, but you can't get yourself out of bed until 8, like maybe that is a sign that you didn't get enough sleep the night before that your sleep is poor quality, but for people who just find it a more pleasant way to wake up and it's kind of built into their daily routine from what I could find. There's nothing wrong with that. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/6330543/rsv-treatment-shortage/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/6330543/rsv-treatment-shortage/"},"headline":"There’s a Shortage of RSV Treatments. Here’s What Doctors Recommend","datePublished":"2023-11-02T14:32:07.000Z","dateModified":"2026-08-04T07:50:48.297Z","description":"Not all babies might get an RSV drug this season, but there are other ways to protect them,","url":"https://time.com/6330543/rsv-treatment-shortage/","keywords":["medicine","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt0c21b99ece6ba404/698a41dc47ca3836ae3bb497/GettyImages-73773306.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt0c21b99ece6ba404/698a41dc47ca3836ae3bb497/GettyImages-73773306.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Newborn babies sleeping in hospital nursery","caption":"Newborn babies sleeping in hospital nursery","creditText":"Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/medicine/","name":"medicine"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/6330543/rsv-treatment-shortage/","name":"There’s a Shortage of RSV Treatments. Here’s What Doctors Recommend"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Hitting the Snooze Button May Not Be as Bad as You Think","description":"Many sleep experts take a dim view of using the snooze button in the morning. But the science on snoozing isn't conclusive.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/z2liolYC/poster.jpg?width=720","uploadDate":"2023-11-02T20:20:41.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/z2liolYC.m3u8","embedUrl":"https://time.com/6330543/rsv-treatment-shortage/","duration":"PT3M","potentialAction":{"@type":"SeekToAction","target":"https://time.com/6330543/rsv-treatment-shortage/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```